Oncoinvent ASA

Share Issue/Capital Change • Dec 10, 2025

Oncoinvent ASA: New share capital registered

Oncoinvent ASA: New share capital registered

10 December 2025: Reference is made to the stock exchange announcements

published by Oncoinvent ASA (the "Company") on 30 June 2025 and 4 August 2025,

and subsequent announcements, regarding the contemplated fully underwritten

rights issue of 260,000,000 new shares in the Company (the "Offer Shares")

raising gross proceeds of NOK 130 million (the "Rights Issue"). Further,

reference is made to the stock exchange announcement published by the Company on

5 December 2025 regarding the resolution by the board of directors of the

Company to issue 31,199,997 new shares in the Company, each with a nominal value

of NOK 0.50, at a subscription price of NOK 0.50 per share (the "Underwriting

Commission Shares") to be delivered to the underwriters pursuant to the

subscription and underwriting agreements dated 30 June 2025 as settlement of

their entitlement to an underwriting fee under said agreements.

The share capital reduction to reduce the nominal value of the shares in the

Company and the share capital increases pertaining to the issuance of the Offer

Shares and the Underwriting Commission Shares have today been registered with

the Norwegian Register of Business Enterprises (Nw. Foretaksregisteret).

The Company's registered share capital following the share capital reduction and

the share capital increases related to the issue of the Offer Shares and the

Underwriting Commission Shares is NOK 223,920,562.50 divided into 447,841,125

shares, each with a nominal value of NOK 0.50.

For further information, please contact:

Oystein Soug, Chief Executive Officer

Email: soug@oncoinvent.com

This information is subject to the disclosure requirements pursuant to Section 5

-12 of the Norwegian Securities Trading Act.

About Oncoinvent

Oncoinvent is a clinical-stage biotechnology company developing novel

radiopharmaceutical therapies against cancer. The lead product candidate,

Radspherin®, uses the alpha-emitting radionuclide radium-224, directly targeting

micro-metastases in the peritoneum post-surgery, harnessing the benefits of

modern radiopharmaceuticals without the complexities of biological targeting.

Oncoinvent is investigating the safety and efficacy of Radspherin® in a clinical

development program in two indications. One Phase 1 trial and one Phase 1/2a

trial have been completed and one randomized Phase 2 trial in ovarian cancer is

currently ongoing in the US and Europe. Early clinical efficacy data are highly

encouraging, and no serious toxicity or safety concerns have been reported to

date. Oncoinvent runs a state-of-the-art manufacturing facility to produce drug

products for clinical trials in Nydalen, Oslo. Oncoinvent is listed on the Oslo

Stock Exchange.

About Radspherin®

Radspherin® is an innovative internal radiation therapy designed to directly

target microscopic metastases in the abdominal cavity following surgery.

Radspherin® is currently in development as a post-surgical treatment for

patients with cancer that has spread to the abdominal cavity - a group with very

limited treatment options today. The drug candidate offers a distinctly unique

therapeutic approach with several differentiating features, including the use of

radium-224, single-dose treatment with a sustained therapeutic effect, non

-systemic administration, direct targeting and an exceptional dose-to-tumor

ratio, maximizing efficacy while limiting harm to healthy tissue.